Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sitagliptin/pioglitazone - Merck & co

Drug Profile

Sitagliptin/pioglitazone - Merck & co

Alternative Names: Janacti; MK-0431C; Pioglitazine/sitagliptin

Latest Information Update: 01 Sep 2014

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Class Antihyperglycaemics; Pyrazines; Small molecules; Thiazolidinediones; Triazoles
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Submission Withdrawal Type 2 diabetes mellitus

Most Recent Events

  • 28 Aug 2014 Takeda completes a 10-year epidemiology study as part of its post-marketing commitment to submit data to the regulatory authorities in the US, EU and Japan for pioglitazone and piogliazone-containing medicines
  • 14 Nov 2011 Regulatory submission withdrawn for Type-2 diabetes mellitus in European Union (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top